TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02725931

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) plus PA-focused intervention
Description: Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
Study: NCT00216710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Visiting
Study: NCT03860597

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: To assess the acute effects of MEM (0 vs. 20 mg) on measures of auditory processing fidelity, auditory learning and EAIP, in AP-medicated adult SZ patients and HS.
Study: NCT04324931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomechanical corrections
Description: Biomechanical corrections is to be done to correct the varus deformity of knee joint and for pain management.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Conventional therapy includes Hydrocollatoral pack for 20 minutes, Interferential therapy for 15 minutes beat frequency 100 Hz, Sweep frequency 150 Hz and exercise program of 3 sessions for 20 minutes on alternative days for 3 weeks for management of knee osteoarthritis.
Study: NCT01743417

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerised cognitive rehabilitation training
Description: 24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised cognitive rehabilitation training
Description: 24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
Study: NCT04043728

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol adapted for smoking cessation
Description: Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol adapted for smoking cessation
Description: Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol adapted for smoking cessation
Description: Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module. All participants will be provided with the American Lung Association Freedom from Smoking guide to aid in their quit attempt.
Study: NCT03003364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XCEL-UMC-BETA
Description: Intrathecal allogeneic cell therapy in a blinded syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a blinded syringe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in a blinded syringe
Study: NCT00377572

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: omalizumab placebo
Description: Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
Study: NCT04006938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Bout ('S')
Description: Each subject will perform a single bout of 30-minutes of moderate-intensity cycling before breakfast

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple Bout ('M')
Description: Each subject will perform three (3) 10-minute bouts of moderate intensity cycling before breakfast, lunch and dinner
Study: NCT02367170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diaphragm thickness measurement
Description: Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
Study: NCT02367170

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Diaphragm thickness measurement
Description: Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and Urine samples
Description: Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
Study: NCT00323622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amodiaquine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amodiaquine
Description: 1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
Study: NCT02367170

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood and Urine samples
Description: Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
Study: NCT03032185

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Elevtrical Nerve Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Elevtrical Nerve Stimulation
Study: NCT00851734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin ophthalmic solution
Description: 0.02%, 0.2% t.i.d. or b.i.d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voclosporin ophthalmic solution
Description: 0.02%, 0.2% t.i.d. or b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: voclosporin ophthalmic solution
Description: 0.02%, 0.2% t.i.d. or b.i.d.
Study: NCT01737008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Tablets are administered orally or through a G-Tube, and can be taken with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacomitinib
Description: Tablets are administered orally or through a G-Tube, and can be taken with or without food.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
Study: NCT06222619

Intervention type: PROCEDURE
Intervention: Potal vein embilization
Description: Portal vein of involved bile duct is embolized to increase the volume of remnant liver.

Intervention type: PROCEDURE
Intervention: Potal vein embilization
Description: Portal vein of involved bile duct is embolized to increase the volume of remnant liver.
Study: NCT01683695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMG 557
Description: AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
Study: NCT02734004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study: NCT00403052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide
Description: 6 weekly subcutaneous (under the skin) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide
Description: 6 weekly subcutaneous (under the skin) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1018 ISS immunostimulatory oligonucleotide
Description: 6 weekly subcutaneous (under the skin) injections
Study: NCT03710603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be given at a dose of 1800 mg SC weekly in Cycles 1 and 2, then every 2 weeks in Cycles 3-6. In maintenance Cycles 7+, subjects will receive daratumumab once every 4 weeks until disease progression or unacceptable toxicity. MRD-negative subjects will stop daratumumab after sustained MRD negativity for 12 months \& after a min. of 24 months of maintenance. Daratumumab should be restarted at recurrence of MRD or confirmed loss of CR without disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
Study: NCT03503331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]PiB-PET/MRI
Description: All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
Study: NCT03710603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
Study: NCT02469831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study: NCT00149656

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: dietary supplement of multivitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: dietary supplement of multivitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: dietary supplement of selenium only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: dietary supplement of selenium only

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study: NCT02909673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fourth R
Description: Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
Study: NCT00793702

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10
Description: rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
Study: NCT03732794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure CryoICE & AtriClip LAA Exclusion
Description: AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
Study: NCT03366259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200Mcg Tab
Description: administration of 200 Mcg of misoprotol rectal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective cesarean section
Description: elective cesarean section for full term patients

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: elective cesarean section
Description: elective cesarean section for full term patients
Study: NCT02255656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab GZ402673
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Study: NCT02941055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber diet
Description: Foods will be delivered with a home delivery chain once a week for 10 wks of each diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein diet
Description: Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
Study: NCT04049474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)
Description: See BCI description.
Study: NCT01934972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CR + DCS (D-cycloserine)
Description: CR + DCS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CR + placebo
Description: CR + placebo
Study: NCT02976922

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic lozenge
Description: 10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
Study: NCT03189719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
Study: NCT02976922

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lozenge
Description: 10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
Study: NCT03864770

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General physical therapy
Description: The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General physical therapy
Description: The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
Study: NCT03890315

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI
Description: In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI
Description: In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses.